Catalyst Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
29/02/2024 11:31
* Catalyst Pharmaceuticals Inc CPRX.OQ reported quarterly
adjusted earnings of 31 cents per share for the quarter ended
in December, higher than the same quarter last year, when the
company reported EPS of 22 cents. The mean expectation of
five analysts for the quarter was for earnings of 27 cents per
share. Wall Street expected results to range from 23 cents to 32
cents per share.
* Revenue rose 82% to $110.57 million from a year ago;
analysts
expected $105.92 million.
* Catalyst Pharmaceuticals Inc's reported EPS for the
quarter was
31 cents.
* The company reported quarterly net income of $34.84
million.
* Catalyst Pharmaceuticals Inc shares had fallen by 13.4%
this
quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 7% in
the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"
Wall Street's median 12-month price target for Catalyst
Pharmaceuticals Inc is $25.00
This summary was machine generated from LSEG data February 29 at
11:31 a.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 0.27 0.31 Beat
Sep. 30 2023 -0.28 -0.29 Missed
Jun. 30 2023 0.36 0.53 Beat
Mar. 31 2023 0.32 0.26 Missed